• Methotrexate: Folate Antagonist Workflows for Immunosuppress

  2026-07-12

  Methotrexate (SKU A4347) from APExBIO empowers researchers to precisely dissect immunosuppressive and apoptotic mechanisms in vitro and in vivo. This article delivers actionable protocols, troubleshooting strategies, and comparative insights rooted in both recent permeability modeling advances and validated laboratory best practices.

• Patient-Derived Gastric Cancer Assembloids Advance Drug Resp

  2026-07-10

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids with stromal cell subpopulations, improving the physiological relevance of in vitro drug response and resistance analyses. The system provides new opportunities for dissecting the tumor microenvironment, enabling more predictive and personalized preclinical drug testing.

• ERK1/2 Inhibition in Translational Liver Research: Beyond On

  2026-07-09

  This thought-leadership article explores the mechanistic significance and translational potential of ERK1/2 inhibition—specifically via the small molecule GDC-0994—in the context of both cancer and emerging hepatic applications. Leveraging recent mechanistic studies, the article provides strategic guidance for researchers bridging oncology and hepatology, highlights protocol best practices, and articulates the competitive and scientific landscape. It concludes with a forward-looking analysis of ERK pathway inhibition for complex disease modeling and therapeutic innovation.

• Hypoxia and Immunometabolism in Tumor Microenvironments: Mec

  2026-07-09

  This review elucidates how hypoxia-driven metabolic and immunological reprogramming creates an immunosuppressive tumor microenvironment, supporting tumor progression. It provides a detailed mechanistic framework for understanding metabolic competition and immune adaptation in hypoxic tumors, with implications for targeted therapeutic strategies.

• ARCA EGFP mRNA (5-moUTP): Precision Polyadenylated mRNA for

  2026-07-08

  ARCA EGFP mRNA (5-moUTP) delivers robust, immune-silent fluorescence for direct transfection monitoring in mammalian cells. Its advanced modifications enable superior stability, translation efficiency, and reproducibility, making it a gold-standard control for fluorescence-based mRNA workflows.

• Nerve-Dependent HDAC1 Regulation in Axolotl Limb Regeneratio

  2026-07-08

  This study uncovers how nerve-mediated upregulation of HDAC1 is essential for limb regeneration in axolotls, revealing a direct link between neural cues, epigenetic regulation, and successful blastema formation. These findings have implications for regenerative biology and inform the use of HDAC inhibitors in both regeneration and cancer research.

• Spleen-Targeted Neoantigen mRNA Vaccines Drive TLS in HCC

  2026-07-07

  Lin et al. introduce a spleen-targeted neoantigen mRNA vaccine (STNvac) that robustly activates ISG15+ CD8+ T cells and induces tertiary lymphoid structures in hepatocellular carcinoma (HCC). This mechanistic advance in organ-specific mRNA vaccine delivery highlights new strategies to overcome immune resistance in solid tumors.

• Marein Competitively Inhibits ABCG2 to Restore Chemosensitiv

  2026-07-07

  The reference study uncovers marein, a natural flavonoid from Coreopsis tinctoria, as a potent competitive inhibitor of the ABCG2 transporter, restoring chemosensitivity in multidrug-resistant cancer cells. By binding a key residue within ABCG2, marein enhances intracellular drug retention, offering a focused mechanistic avenue for overcoming cancer drug resistance.

• LY364947: Precision Control of TGF-β Signaling in EMT and Fi

  2026-07-06

  Explore how LY364947, a potent TGF-β type I receptor kinase inhibitor, enables unprecedented precision in modulating epithelial-mesenchymal transition (EMT) and fibrosis. This article delves into mechanistic insights, comparative advantages, and advanced preclinical applications, offering researchers a uniquely actionable guide.

• HyperScribe T7 High Yield Cy3 RNA Labeling Kit: Advanced Wor

  2026-07-06

  The HyperScribe T7 High Yield Cy3 RNA Labeling Kit empowers researchers to efficiently synthesize high-yield, customizable fluorescent RNA probes for sensitive detection in in situ hybridization and Northern blot assays. Streamlined protocols, robust troubleshooting, and cross-validated data put APExBIO’s solution at the center of next-generation molecular workflows.

• Apicidin as a Histone Deacetylase Inhibitor: Applied Workflo

  2026-07-05

  Apicidin is more than a selective HDAC inhibitor—it bridges cancer research, reproductive toxicology, and epigenetic assay design. This guide details how to unlock Apicidin’s full potential in experimental settings, with actionable workflows, troubleshooting advice, and direct translation of new findings.

• PPACK Dihydrochloride: Rethinking Thrombin Inhibition in Pla

  2026-07-04

  This thought-leadership article analyzes the mechanistic underpinnings and translational strategy behind using PPACK Dihydrochloride as a high-precision thrombin inhibitor in platelet and blood coagulation research. Integrating recent findings on platelet purinergic signaling and referencing both foundational and advanced protocol literature, it explores how researchers can leverage APExBIO's PPACK Dihydrochloride to design more selective, reproducible assays and anticipate the next wave of antithrombotic drug development.

• Streptavidin-Cy3: Precision Biotin Detection in NPC Metastas

  2026-07-03

  Streptavidin-Cy3 empowers researchers with ultra-sensitive, quantitative detection of biotinylated targets in complex cancer workflows. Its high-affinity binding and Cy3-based fluorescence enable robust immunohistochemistry and in situ hybridization, ideal for dissecting mechanistic pathways in nasopharyngeal carcinoma metastasis.

• LDH Cytotoxicity Assay Kit: Practical Guide and Workflow Set

  2026-07-03

  The LDH Cytotoxicity Assay Kit (SKU K2228) addresses the need for a reliable, non-radioactive method of quantifying cell damage by measuring LDH released from compromised cells. This product is best suited for apoptosis detection, cell viability assessment, and cytotoxicity testing in research models, but should not be used to infer mechanistic details of cell death without complementary assays.

• Lypressin Acetate: Mechanistic Evidence & Clinical Benchmark

  2026-07-02

  Lypressin acetate, a lysine vasopressin analog, is a validated G protein-coupled receptor agonist used in the treatment of diabetes insipidus. Peer-reviewed evidence supports its distinct pharmacological activity profile and emerging antiviral properties, with precise dosing and stability requirements critical for reproducible research and clinical outcomes.

455 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page